Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022

Global aprela market: Latest market research analysed


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-14 02:55:03 - Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "Aprela (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the gold-standard bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lillys blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs

 

 

with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

Aprela (bazedoxifene and conjugated estrogens) is a once-daily oral product that combines the third-generation SERM bazedoxifene with conjugated estrogens. It is the first drug belonging to the novel class of tissue selective estrogen complexes (TSECs), which pair an SERM with estrogen(s). Originally developed by Ligand Pharmaceuticals and Wyeth through a collaboration that began in 1994, Pfizer acquired the rights to the product as part of its acquisition of Wyeth. In July 2012, Pfizer submitted a Marketing Authorization Application (MAA) to the EMA for the combination products use in postmenopausal women with a uterus for the treatment of estrogen-deficiency symptoms and the treatment of osteoporosis in women at risk of fracture. In December 2012, Pfizer submitted an NDA to the FDA for US regulatory approval of Aprela for the treatment of menopausal symptoms and the prevention of postmenopausal osteoporosis. As discussed in greater detail below, this combination drug has demonstrated positive efficacy and safety results in a series of Phase III clinical trials involving approximately 7,500 women, but bazedoxifenes US regulatory history will likely lead Aprela to be subjected to particularly rigorous scrutiny.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

- Overview of Osteoporosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aprela including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aprela for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aprela performance
- Obtain sales forecast for Aprela from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com